Zobrazeno 1 - 10
of 145
pro vyhledávání: '"Ibiayi Dagogo‐Jack"'
Autor:
Benjamin J. Solomon, M.B.B.S., PhD, Ibiayi Dagogo-Jack, MD, Se-Hoon Lee, MD, Michael J. Boyer, M.B.B.S., PhD, Suresh S. Ramalingam, MD, Enric Carcereny, MD, Enriqueta Felip, MD, PhD, Ji-Youn Han, MD, PhD, Toyoaki Hida, PhD, Brett G.M. Hughes, M.B.B.S., Sang-We Kim, MD, PhD, Makoto Nishio, MD, PhD, Takashi Seto, MD, Tatsuro Okamoto, MD, PhD, Xiaoxi Zhang, PhD, Jean-Francois Martini, PhD, Erjian Wang, MD, PhD, Steven De Beukelaer, MD, Todd M. Bauer, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 7, Pp 100685- (2024)
Introduction: The JAVELIN Lung 101 phase 1b/2 trial evaluated avelumab (immune checkpoint inhibitor) combined with lorlatinib or crizotinib (tyrosine kinase inhibitors) in ALK-positive or ALK-negative advanced NSCLC, respectively. Methods: Starting d
Externí odkaz:
https://doaj.org/article/50d39c846b474baea88547c6b345e6aa
Autor:
Susan Raju Paul, Ivan Valiev, Skylar E. Korek, Vladimir Zyrin, Diana Shamsutdinova, Olga Gancharova, Alexander Zaitsev, Ekaterina Nuzhdina, Diane L. Davies, Ibiayi Dagogo‐Jack, Felix Frenkel, Jessica H. Brown, Joshua M. Hess, Sarah Viet, Jason L. Petersen, Cameron D. Wright, Harald C. Ott, Hugh G. Auchincloss, Ashok Muniappan, Toshihiro Shioda, Michael Lanuti, Christel M. Davis, Erik A. Ehli, Yin P. Hung, Mari Mino‐Kenudson, Maria Tsiper, Ann E. Sluder, Patrick M. Reeves, Nikita Kotlov, Alexander Bagaev, Ravshan Ataullakhanov, Mark C. Poznansky
Publikováno v:
FASEB BioAdvances, Vol 5, Iss 4, Pp 156-170 (2023)
Abstract Lung cancer is the leading cause of cancer‐related deaths worldwide. Surgery and chemoradiation are the standard of care in early stages of non‐small cell lung cancer (NSCLC), while immunotherapy is the standard of care in late‐stage N
Externí odkaz:
https://doaj.org/article/2fdae20227e943d885e32ad85125e390
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 9, Pp 100557- (2023)
Introduction: Guidelines recommend obtaining a computed tomography scan of the chest for the staging of pleural mesothelioma and for assessing response to treatment. Consensus is lacking regarding the necessity of serial imaging of distant extrathora
Externí odkaz:
https://doaj.org/article/0437944dbe2843fc829e9c2a1d154d1d
Autor:
Ibiayi Dagogo-Jack, MD, Lesli A. Kiedrowski, MS, MPH, Rebecca S. Heist, MD, MPH, Jessica J. Lin, MD, Catherine B. Meador, MD, PhD, Elizabeth A. Krueger, NP, Andrew Do, BS, Jennifer Peterson, BS, Lecia V. Sequist, MD, MPH, Justin F. Gainor, MD, Jochen K. Lennerz, MD, PhD, Subba R. Digumarthy, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 8, Pp 100534- (2023)
Introduction: MET amplification is a potentially actionable resistance mechanism in ALK-rearranged (ALK+) lung cancer. Studies describing treatment outcomes of this molecular subgroup are lacking. Methods: We assembled a cohort of patients with ALK+
Externí odkaz:
https://doaj.org/article/48f3d6a56b8d4f66bc9f438add97a0a8
Autor:
Ibiayi Dagogo-Jack, MD, Ivan Valiev, MD, Nikita Kotlov, MS, Anna Belozerova, MD, Aleksandra Lopareva, MS, MD, Anna Butusova, MS, Naira Samarina, PhD, Alexandra Boyko, MS, Zhongmin Xiang, PhD, Monique Johnson, BS, Sandrine Degryse, PhD, Florence K. Keane, MD, Lecia V. Sequist, MD, Michael Lanuti, MD, Nathan Fowler, MD, Mari Mino-Kenudson, MD, Alexander Bagaev, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 7, Pp 100527- (2023)
Introduction: Relapse is common after resection of lung adenocarcinoma (LUAD). Features of the tumor microenvironment (TME) which influence postsurgical survival outcomes are poorly characterized. Here, we analyzed the TME of more than 1500 LUAD spec
Externí odkaz:
https://doaj.org/article/acbc54d5c39b41eeb5768d2ee56dbc4c
Autor:
Mary C. Boulanger, MD, Jennifer S. Temel, MD, Mari Mino-Kenudson, MD, Lauren L. Ritterhouse, MD, PhD, Ibiayi Dagogo-Jack, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100501- (2023)
The NTRK genes encode the TRK proteins. NTRK fusions lead to constitutively active, ligand-independent downstream signaling. NTRK fusions are implicated in up to 1% of all solid tumors and 0.2% of NSCLC. Larotrectinib, a highly selective small molecu
Externí odkaz:
https://doaj.org/article/4f543e45c5e04d4c99b768fed1a7106e
Autor:
Priscilla K. Brastianos, Matthew R. Strickland, Eudocia Quant Lee, Nancy Wang, Justine V. Cohen, Ugonma Chukwueke, Deborah Anne Forst, April Eichler, Beth Overmoyer, Nancy U. Lin, Wendy Y. Chen, Aditya Bardia, Dejan Juric, Ibiayi Dagogo-Jack, Michael D. White, Jorg Dietrich, Naema Nayyar, Albert E. Kim, Christopher Alvarez-Breckenridge, Maura Mahar, Joana L. Mora, Brian V. Nahed, Pamela S. Jones, Helen A. Shih, Elizabeth R. Gerstner, Anita Giobbie-Hurder, Scott L. Carter, Kevin Oh, Daniel P. Cahill, Ryan J. Sullivan
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-7 (2021)
Leptomeningeal metastases from solid tumors are a rare complication with a very poor prognosis. Here the authors report the efficacy and safety of combined ipilimumab and nivolumab in patients with leptomeningeal carcinomatosis.
Externí odkaz:
https://doaj.org/article/b04f3eeb51ed4432b18eeaf9f4a73076
Autor:
Alissa J. Cooper, MD, Alona Muzikansky, MA, Jochen Lennerz, MD, PhD, Farhaana Narinesingh, M.B.B.S., Mari Mino-Kenudson, MD, Yin P. Hung, MD, PhD, Zofia Piotrowska, MD, MHS, Ibiayi Dagogo-Jack, MD, Lecia V. Sequist, MD, MPH, Justin F. Gainor, MD, Jessica J. Lin, MD, Rebecca S. Heist, MD, MPH
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100390- (2022)
Introduction: Co-occurring mutations in KRAS-mutant NSCLC are associated with discrete biological properties and modulate therapeutic susceptibilities. As G12D-specific inhibitors are expected to enter the clinic, we sought to investigate the charact
Externí odkaz:
https://doaj.org/article/b74d2bef942c4556b6ea5685e2ff735a
Autor:
Jaime L. Schneider, MD, PhD, Alona Muzikansky, MA, Jessica J. Lin, MD, Elizabeth A. Krueger, NP, Inga T. Lennes, MD, Joseph O. Jacobson, MD, Michael Cheng, MD, Rebecca S. Heist, MD, MPH, Zofia Piotrowska, MD, MHS, Justin F. Gainor, MD, Alice T. Shaw, MD, PhD, Ibiayi Dagogo-Jack, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 7, Pp 100347- (2022)
Introduction: The central nervous system (CNS) is a common site of progression among patients with ROS1-rearranged lung cancer receiving crizotinib. We conducted a phase 2 study to evaluate the intracranial efficacy of lorlatinib in patients with ROS
Externí odkaz:
https://doaj.org/article/93980cd67c144363bbe8189dbeede26f
Autor:
Andrew J. Piper-Vallillo, MD, Meghan J. Mooradian, MD, Catherine B. Meador, MD, PhD, Beow Y. Yeap, ScD, Jennifer Peterson, BS, Mustafa Sakhi, BS, MS, Andrew Do, BS, Leyre Zubiri, MD, Sara Stevens, NP, Jeanne Vaughn, NP, Kelly Goodwin, NP, Alexander Gavralidis, MD, Henning Willers, MD, Adam Miller, MD, Anna Farago, MD, PhD, Zofia Piotrowska, MD, MHS, Jessica J. Lin, MD, Ibiayi Dagogo-Jack, MD, Inga T. Lennes, MD, MPH, MBA, Lecia V. Sequist, MD, MPH, Jennifer S. Temel, MD, Rebecca S. Heist, MD, Subba Digumarthy, MD, Kerry L. Reynolds, MD, Justin F. Gainor, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 1, Pp 100124- (2021)
Introduction: Lung cancer is associated with severe coronavirus disease 2019 (COVID-19) infections. Symptom overlap between COVID-19 and lung cancer may complicate diagnostic evaluation. We aimed to investigate the incidence, symptoms, differential d
Externí odkaz:
https://doaj.org/article/899d24b36a34456388b6d820eedce98b